Shanghai RAAS Blood Products Co Ltd Class A (002252) — Cash Flow Reinvestment Rate
Shanghai RAAS Blood Products Co Ltd Class A (002252) has a Cash Flow Reinvestment Rate of 0.41x as of March 2025, reinvesting CN¥317.67 Million (capex CN¥62.51 Million plus investments CN¥255.16 Million) from operating cash flow of CN¥775.56 Million. Check Shanghai RAAS Blood Products Co Ltd Clas cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Shanghai RAAS Blood Products Co Ltd Class A Cash Flow Reinvestment Rate (2005–2023)
Historical reinvestment intensity for Shanghai RAAS Blood Products Co Ltd Class A across 18 annual periods. Explore 002252 operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
Annual Cash Flow Reinvestment Rate for Shanghai RAAS Blood Products Co Ltd Class A (2005–2023)
Year-by-year capital reinvestment analysis for Shanghai RAAS Blood Products Co Ltd Class A. For live market cap and broader valuation context, see 002252 stock market capitalisation.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2023 | 0.49x | CN¥1.12 Billion | CN¥2.28 Billion | CN¥450.80 Million | ▼ -27.5% |
| 2022 | 0.68x | CN¥1.17 Billion | CN¥1.73 Billion | CN¥225.73 Million | ▲ +8.0% |
| 2021 | 0.63x | CN¥814.12 Million | CN¥1.29 Billion | CN¥204.61 Million | ▲ +17.7% |
| 2020 | 0.53x | CN¥624.78 Million | CN¥1.17 Billion | CN¥251.76 Million | ▲ +172.1% |
| 2019 | 0.20x | CN¥171.43 Million | CN¥872.69 Million | CN¥154.84 Million | ▼ -94.6% |
| 2018 | 3.66x | CN¥959.60 Million | CN¥262.50 Million | CN¥156.94 Million | ▼ -42.4% |
| 2017 | 6.35x | CN¥1.71 Billion | CN¥268.76 Million | CN¥157.84 Million | ▲ +273.3% |
| 2016 | 1.70x | CN¥1.08 Billion | CN¥638.22 Million | CN¥147.49 Million | ▲ +791.5% |
| 2015 | 0.19x | CN¥145.39 Million | CN¥762.42 Million | CN¥145.39 Million | ▲ +36.6% |
| 2014 | 0.14x | CN¥65.06 Million | CN¥465.96 Million | CN¥65.06 Million | ▼ -75.4% |
| 2012 | 0.57x | CN¥149.70 Million | CN¥263.46 Million | CN¥149.70 Million | ▼ -42.8% |
| 2011 | 0.99x | CN¥176.80 Million | CN¥178.03 Million | CN¥176.80 Million | ▲ +122.9% |
| 2010 | 0.45x | CN¥89.21 Million | CN¥200.21 Million | CN¥89.21 Million | ▼ -15.2% |
| 2009 | 0.53x | CN¥60.99 Million | CN¥116.01 Million | CN¥60.99 Million | ▲ +93.6% |
| 2008 | 0.27x | CN¥29.23 Million | CN¥107.64 Million | CN¥29.23 Million | ▲ +95.1% |
| 2007 | 0.14x | CN¥24.46 Million | CN¥175.71 Million | CN¥24.46 Million | ▼ -38.3% |
| 2006 | 0.23x | CN¥12.08 Million | CN¥53.58 Million | CN¥12.08 Million | ▼ -43.8% |
| 2005 | 0.40x | CN¥21.69 Million | CN¥54.02 Million | CN¥21.69 Million | — |